GRP
IMDX

Global Retirement Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Global Retirement Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+1
New +$5 ﹤0.01% 4503
2025
Q4 		$8 Hold
1
– – ﹤0.01% 4213
2025
Q3 		$3 Hold
1
– – ﹤0.01% 3860
2025
Q2 		$3 Buy
+1
New +$3 ﹤0.01% 3797

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Global Retirement Partners's IMDX Position: Q2 2026 in Review

Global Retirement Partners opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #4503 among its holdings. This is a return to the name: Global Retirement Partners previously reported a position in IMDX as recently as Q4 2025.

Global Retirement Partners first reported a position in IMDX in Q2 2025 and has held it in 4 quarters since. The position peaked at $8 in Q4 2025. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Global Retirement Partners held 1 share of Insight Molecular Diagnostics worth $6 as of Q2 2026.
  • Insight Molecular Diagnostics was a new Global Retirement Partners position in Q2 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Global Retirement Partners's portfolio in Q2 2026, its #4503 holding.
  • Global Retirement Partners first reported a position in Insight Molecular Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • Global Retirement Partners's Insight Molecular Diagnostics position peaked at $8 in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Global Retirement Partners's 13F filing for Q2 2026, filed 6 Aug 2026.